276P - Electrochemotherapy for breast cancer - results from the INSPECT database

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Breast Cancer
Presenter Louise Matthiessen
Citation Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365
Authors L.W. Matthiessen1, M. Keshtgar2, C. Kunte3, E. Grischke4, J. Odili5, T. Muir6, P. Curatolo7, D. Mowatt8, J. Clover9, S.H. Liew10, H.F. Hansen11, J. Newby12, V. Letulé3, E. Stauss4, A.C. Humphreys13, S. Banerjee14, A. Klein15, F. de Terlizzi16, J. Gehl11
  • 1Department Of Oncology, Copenhagen University Hospital Herlev and Gentofte, 2730 - Herlev/DK
  • 2Department Of Plastic Surgery, Royal Free London NHS foundation trust, London/GB
  • 3Department Of Dermatology And Allergology, Ludwig Maximilians University, München/DE
  • 4Department Of Oncology, Universitet Frauenklinik Tübingen, Tübingen/DE
  • 5Department Of Plastic Surgery, St George's Hospital NHS Trust, London/GB
  • 6Department Of Plastic Surgery, The James Cook University Hospital, Middlesbrough/GB
  • 7Department Of Internal Medicine And Medical Specialties, Sapienza – Università di Roma, Roma/IT
  • 8Department Of Plastic Surgery, The Christie NHS Foundation Trust, Manchester/GB
  • 9Department Of Plastic Surgery, Cork University Hospital, Cork/IE
  • 10Department Of Plastic Surgery, Liverpool Hospital, Liverpool/GB
  • 11Department Of Oncology, Copenhagen University Hospital Herlev and Gentofte, Herlev/DK
  • 12Department Of Oncology, Royal Free London NHS foundation trust, London/GB
  • 13Department Of Oncology, The James Cook University Hospital, Middlesbrough/GB
  • 14Division Of Surgery And Interventional Science, Royal Free London NHS foundation trust, London/GB
  • 15Department Of Dermatologic Surgery And Dermatology, Artemed Fachklinik, München/DE
  • 16Scientific & Medical Department, IGEA, Carpi/IT



Cutaneous recurrence from breast cancer can pose a clinical challenge. It may be the only disease site, or be part of disseminated disease, and often profoundly impacts quality of life. Electrochemotherapy is a palliative treatment for cutaneous metastases. Using electric pulses to locally permeabilize tumor cells, bleomycin cytotoxicity is significantly increased. Collaborating in the International Network for sharing Practice on ElectroChemoTherapy (INSPECT), we consecutively and prospectively accrued data on patients treated with electrochemotherapy for skin metastases of breast cancer.


Patients with cutaneous metastases were treated with electrochemotherapy at 10 European centers. Treatment data and results were entered into the INSPECT database. Patients were treated with either local injection (1000 IU/ml intratumoral injection) or systemic infusion (15.000 IU/m2) of bleomycin, and under either local or general anesthesia, depending on tumor size. Pulse sequences (8 pulses of 0.1 ms) were sequentially applied to the tumor area, using an electroporation system with needle or plate electrodes (IGEA, Italy).


104 patients were included. Median age was 65 years. Patients had previous received chemotherapy (87%), radiotherapy (83%), endocrine therapy (46%) and HER2 targeted therapy (20%). Primary location was the chest (87%), median diameter of the cutaneous metastases being 26 mm (range 1 mm to 550 mm). 75 patients were available for response evaluation after 2 months. Complete response was observed in 38 (51%) patients, partial response in 13 (17%), stable disease in 14 (19%), and progressive disease in 5 (9%), 3 patients were not evaluable. Common side effects were ulceration, long lasting hyperpigmentation, and slight increase in pain. No serious adverse events were observed.


Electrochemotherapy showed high response rates, particularly in smaller metastases. Electrochemotherapy has high response rates seen after a single treatment, with few side effects and can be used as an adjunct to systemic therapies as well as a sole treatment. We therefore highly recommend to consider electrochemotherapy for patients with cutaneous metastases, where radiotherapy and surgery is not an option.

Clinical trial identification

Legal entity responsible for the study

Each center participating in the study are responsible for governance and running of the study, and are legally responsible for the study at their own institution. Coordination was performed by investigators at one center elected by the International Network of Sharing Practices of Electrochemotherapy, which is a collaboration of between clinicians and centers performing electrochemotherapy.


The study is funded by each center. IGEA, Carpi, Italy is funding and maintaining the database, where the INSPECT members upload data.


F. de Terlizzi: Employee in IGEA, Carpi, Italy. All other authors have declared no conflicts of interest.